secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001193125-25-024838
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Therapeutics secures $105M private placement to fund Phase 2 hepatitis B study
--------------------------------------------------------------------------------

- Gross proceeds ~$105M from sale of 2.1M shares, pre-funded warrants (1.9M shares), and warrants (2.0M shares); closing expected Feb 13, 2025.
- Combined price $26.0825 per share/warrant; warrants exercisable at $26.02, expire Feb 13, 2032; pre-funded warrants at $0.0001.
- Net proceeds to fund ALG-000184 Phase 2 study in chronic hepatitis B; cash runway extended into H2 2026.
- Placement led by life sciences investor; Jefferies and Piper Sandler as agents; lead investor gets board nomination rights.
- Company to file resale registration statement within 45 days; securities sold in private placement exempt from registration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312525024838/0001193125-25-024838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312525024838/d901857d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-024838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer